TIL therapy and anti-CTLA4: can they co-exist?
TIL therapy and anti-CTLA4: can they co-exist? |
|
https://doi.org/10.18632/oncotarget.26509
Marie-Andrée Forget,
Cara Haymaker,
Rodabe N. Amaria,
and Chantale Bernatchez
|
| 1-2 |
Multidimensional intratumour heterogeneity in neuroblastoma
Multidimensional intratumour heterogeneity in neuroblastoma |
|
https://doi.org/10.18632/oncotarget.26524
Kristoffer von Stedingk,
David Gisselsson,
and Daniel Bexell
|
| 3-5 |
Role of acid sphingomyelinase-induced ceramide generation in response to radiation
Role of acid sphingomyelinase-induced ceramide generation in response to radiation |
|
https://doi.org/10.18632/oncotarget.26526
Deepa Sharma,
and Gregory J. Czarnota
|
| 6-7 |
Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars
Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
|
https://doi.org/10.18632/oncotarget.26528
Hans-Christian Kolberg,
Gunter von Minckwitz,
and Vladimir Hanes
|
| 8-9 |
Combination of lenalidomide and vitamin D enhances MOR202-mediated cytotoxicity of macrophages: It takes three to tango
Combination of lenalidomide and vitamin D enhances MOR202-mediated cytotoxicity of macrophages: It takes three to tango |
|
https://doi.org/10.18632/oncotarget.26531
Cindy Flamann,
Leonhard Busch,
Andreas Mackensen,
and Heiko Bruns
|
| 10-12 |
Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs)
Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs) |
|
https://doi.org/10.18632/oncotarget.26535
Alfredo Perales-Puchalt,
Elizabeth K. Duperret,
Kar Muthumani,
and David B. Weiner
|
| 13-16 |
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate |
|
https://doi.org/10.18632/oncotarget.26523
Leonidas Apostolidis,
Cathleen Nientiedt,
Eva Caroline Winkler,
Anne Katrin Berger,
Clemens Kratochwil,
Annette Kaiser,
Anne-Sophie Becker,
Dirk Jäger,
Markus Hohenfellner,
Clemens Hüttenbrink,
Sascha Pahernik,
Florian A. Distler,
and Carsten Grüllich
|
| 17-29 |
FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells |
|
https://doi.org/10.18632/oncotarget.26530
Ming Zhao,
Ming-Lei Zhuo,
Xiaofeng Zheng,
Xiaoping Su,
and Funda Meric-Bernstam
|
| 30-44 |
Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells
Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells |
|
https://doi.org/10.18632/oncotarget.26534
Esraah Alharris,
Narendra P. Singh,
Prakash S. Nagarkatti,
and Mitzi Nagarkatti
|
| 45-59 |
Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia
Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia |
|
https://doi.org/10.18632/oncotarget.26538
Renee C. Tschumper,
Tait D. Shanafelt,
Neil E. Kay,
and Diane F. Jelinek
|
| 60-75 |
Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma
Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma |
|
https://doi.org/10.18632/oncotarget.26539
Goro Kasuya,
Hiroshi Tsuji,
Takuma Nomiya,
Hirokazu Makishima,
Yasuo Haruyama,
Gen Kobashi,
Kazuhiko Hayashi,
Daniel K. Ebner,
Tokuhiko Omatsu,
Riwa Kishimoto,
Shigeo Yasuda,
Tatsuo Igarashi,
Mototsugu Oya,
Koichiro Akakura,
Hiroyoshi Suzuki,
Tomohiko Ichikawa,
Jun Shimazaki,
and Tadashi Kamada and the Working Group for Genitourinary Tumors
|
| 76-81 |
